Treatment of Alzheimer’s Disease with Clioquinol
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer’s disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer’s disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, iron chelators have demonstrated therapeutic benefits in Alzheimer's [1674,1710,1769-1771], Parkinson's [1037,1729,1772], cold-induced brain injury [1773,1774], coronary disease [714,797], renal diseases [1775], various kinds of infection [1763] and of course in iron overload diseases [1762,1767].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1771]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationIntramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationThe Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy.
Mohs, R. C., Rosen, W. G., & Davis, K. L. (1983) · PubMed · Cited by 425
Primary structure and transcriptional regulation of GAP-43, a protein associated with nerve growth
Basi, G. S., Jacobson, R. D., Virág, I., Schilling, J., & Skene, J. H. P. (1987) · Cell · doi:10.1016/0092-8674(87)90616-7 · Cited by 355
Cited by
Items 201–222 of 222
Metals Involvement in Alzheimer’s Disease Pathogenesis
Squitti, R., & Salustri, C. (2011) · InTech eBooks · doi:10.5772/16880 · Cited by 1
“In the early 2000s, clioquinol was tested in man revealing that a treatment of just 21 days resulted in a significant improvement of patients’ cognitive performance (Regland et al., 2001).”
Schmued, L. C., Maloney, B., Schmued, C., & Lahiri, D. K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221285 · Cited by 2
“Finally,despite theirclinicalapplicationfortreatingacutemetaltoxi-city, the use of metal chelators for the treatment of AD was not definitive [11].”
BackgroundA Zinc—Potassium Continuum in Neuronal Apoptosis
Redman, P. T., Knoch, M. E., & Aizenman, E. (2009) · Contemporary clinical neuroscience · doi:10.1007/978-1-60327-579-8_6 · Cited by 1
Copper and Alzheimer Disease: The Good, the Bad and the Ugly
Hung, Y. H., Bush, A. I., & Cherny, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9663-3_30 · Cited by 1
Zinc-dependent potassium channel modulation mediates neuronal apoptosis
Redman, P. T. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
Cooperative calcium and zinc signaling underlies oxidantinduced neuronal injury
McCord, M. C. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
NEW DRUGS IN CLINICAL TRIALS FOR TREATMENT OF ALZHEIMER'S DISEASE
Pietrovski, E. F., Sofka, D. C. K., & Claudino, R. F. (2015) · Visão Acadêmica · doi:10.5380/acd.v16i2.40970
Kollalpitiya, K. Y. (2011) · Holmes Museum Of Anthropology (Wichita State University)
Tobias, D. E., & Guay, D. R. P. (2004) · The Consultant Pharmacist · doi:10.4140/tcp.n.2004.629
Moshirpour, M. (2017) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/26778
Biometal homeostasis as a therapeutic strategy in autism spectrum disorders
Grabrucker, A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821132-8.00013-6
(2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.574
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt063
(2004) · CRC series in modern nutrition science · doi:10.1201/9780203489673.ch5
Chen, J., Zeng, Y., Zhu, N., Zhou, Y., Zhong, H., Zhang, X., Sun, W., Chen, J., & Han, Z. (2025) · Journal of Alloys and Compounds · doi:10.1016/j.jallcom.2025.185496
Copper Homeostasis and Cuproptosis in Neurodegenerative Diseases
Liu, B., Zhang, L., Lv, B., Xu, C., Han, L., Yan, Q., & Wang, X. (2026) · Cells · doi:10.3390/cells15141238
Ristau, P. A., Maret, W., & Ristau, T. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7643480
Metadata
- Authors
- Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjögren, M., Wallin, A., Xilinas, M., & Gottfries, C.-G.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 12
- Issue
- 6
- Pages
- 408-414
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2079722596
- Cited by
- 220
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 4 · 2015: 10 · 2014: 9 · 2013: 4 · 2012: 20
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- Alzheimer's disease, clioquinol, metal chelation, zinc, copper, blood-brain barrier, amyloid plaques, cerebrospinal fluid, tau protein, GAP-43, serum copper, copper/zinc ratio, clinical improvement
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Chelating Agents, Copper, Dose-Response Relationship, Drug, Female, Humans, Clioquinol, Male, Middle Aged, Zinc, Chelation Therapy, tau Proteins, Treatment Outcome, GAP-43 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.